Previous 10 | Next 10 |
When it comes to penny stocks to buy , most are usually looking for day trading opportunities. That means time frames are shorter term, in general. If you’re new to trading cheap stocks, you might be thinking about investing in them because of their low price. But it’s als...
Gainers: Avadel Pharmaceuticals AVDL +61%. PMV Pharmaceuticals PMVP +25%. Alpha Tau Medical (DRTS) +18%. SIGA Technologies SIGA +18%. Allarity Therapeutics (ALLR) +17%. Losers: Iovance Biotherapeutics (IOVA) -54%. SpringWorks Therapeutics SWTX...
Gainers: Allarity Therapeutics (ALLR) +13%. Better Therapeutics (BTTX) +19%. GeoVax Labs GOVX +10%. Insulet PODD +7%. MDxHealth (MDXH) +5%. Losers: INmune Bio (INMB) -29%. Liquidia (LQDA) -21%. TherapeuticsMD (TXMD) -19%. Aethlon Medical (AEMD) -14%....
Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides...
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%. PyroGenesis Canada (PYR) +17%. Evofem Biosciences ...
Cambridge, MA U.S.A. ( May 1 8 , 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corpor...
Allarity Therapeutics press release (NASDAQ:ALLR): Q4 net loss was $16.8M for the three months ended December 31, 2021, and $26.6M for the full year 2021, compared to $1.7M and $6.6M for comparable periods in 2020, respectively. As of December 31, 2021, Allarity’s cash was $19.6M,...
Cambridge, MA U.S.A. ( May 16 , 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostic...
Allarity Therapeutics (NASDAQ:ALLR) on Friday said it got a Nasdaq notice on April 20 that it was no longer in compliance with listing rules due to delay in its 10-K filing for the fiscal year ended Dec. 31, 2021. ALLR has 60 days to submit to Nasdaq a plan to regain compliance. If Nasdaq acc...
Cambridge, MA U.S.A. ( April 22 , 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP ® co...
News, Short Squeeze, Breakout and More Instantly...
Allarity Therapeutics Inc. Company Name:
ALLR Stock Symbol:
NASDAQ Market:
Allarity Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Boston (July 24, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, encourages its stockholders to participate actively in the ...
Current Cash Balance of $20 million Expected to Provide Runway Into 2026 Allarity to Pause Use of ATM Cap Table Successfully Cleaned Up Allarity’s Stenoparib Shows Extended Duration of Phase 2 Clinical Benefit Boston (July 22, 2024)—Allarity The...